Bloomberg Daybreak Asia: Early Talks on H200s to China (Podcast)

U.S. officials are in early discussions about whether to permit Nvidia to sell its H200 AI chips to China, a development that could influence the company’s addressable market and the China AI supply chain but remains unresolved. Podcast guests highlighted continued appetite for AI-related risk assets, while markets are awaiting shutdown-delayed economic releases and the Fed’s Beige Book; recent consumer sentiment and stable, high-quality (“Steady Eddie”) companies are shaping investor positioning into the new year.

Analysis

Market structure: Approval to ship H200s materially enlarges NVDA's addressable GPU TAM in China and gives it incremental pricing power versus AMD/Intel for high-end datacenter workloads; model a 10–20% uplift in GPU revenue contribution to NVDA over 12–24 months if shipments scale. Winners include NVDA, hyperscalers with AI workloads (improved unit economics), and component suppliers (TSMC, SK Hynix); losers are mid-tier GPU rivals and Chinese incumbents whose roadmap acceleration could be postponed. On supply/demand, constrained wafer/TSV/HBM capacity means initial shipments will bid up ASPs rather than flood the market, supporting NVDA margins near-term. Cross-asset: an approval-driven risk-on move would likely push 2s–10s yields +10–30bp, compress NVDA options IV by 10–25%, weaken USD ~0.5–1% versus CNY/ CNH, and raise industrial metal demand marginally (copper/rare earths) through fab expansion signals.

Risk assessment: Tail risks include a sudden reversal of permission (supply cutoff), secondary sanctions on end-users, or Chinese firmware/activation limits that hollow out revenue — each could wipe 15–30% off NVDA EPS in a quarter. Immediate horizon (days): elevated NVDA IV and headline sensitivity; short-term (weeks–months): order flow and bookings volatility; long-term (2–5 years): accelerated Chinese indigenization could erode share by 5–15%. Hidden dependencies: TSMC/ASML capacity, HBM supply, and US export-control carve-outs (firmware locks) determine realized upside. Key catalysts: Commerce determination (0–90 days), NVDA guidance updates, and first shipment confirmations from Chinese customers.

Trade implications: Direct: establish a 2–3% portfolio long in NVDA (ticker NVDA) using Jan 2027 LEAPs (50–60 delta) to capture structural upside while limiting capital; size can scale to 4–6% on confirmed approval within 60 days. Hedge with 30–50% notional of 6–9 month 10–12% OTM puts to cap drawdown; alternatively implement a 3-month 5/15% call spread (buy ATM, sell +15% OTM) sized to 1–2% notional to play near-term binary. Pair trade: long NVDA / short AMD (AMD) 1:0.6 notional to express share gain versus ASP pressure. Rotate 3–5% from cyclical semicap names into Steady Eddie consumer staples (XLP) if denial occurs.

Contrarian angles: Consensus treats approval as binary upside; market is underpricing the scenario where approval comes with firmware restrictions that deliver revenue but not full ASPs — downside limited but upside capped. Reaction may be underdone in longer-dated LEAPs (buy-side opportunity) and overdone in near-term stock moves (sell volatility spikes). Historical parallel: partial access after export-control relaxations (2010s) produced a two-year revenue tailwind followed by accelerated local competition; unintended consequence: approval could trigger Chinese capex that accelerates domestic substitutes within 24–36 months, limiting multi-year moats.

Key Decisions for Investors

• Establish a 2–3% portfolio long NVDA via Jan 2027 LEAP calls (50–60 delta); increase to 4–6% only if US approval confirmed within 60 days and first shipment announced.
• Buy 30–50% notional protection via 6–9 month 10–12% OTM puts on NVDA to cap downside in case of denial or sanctions; alternatively sell a 3-month 5/15% call spread (buy ATM, sell +15% OTM) sized to 1–2% notional to capture near-term binary outcomes.
• Initiate a relative-value pair: long NVDA / short AMD sized 1:0.6 to express NVDA share capture and AMD ASP pressure; trim the short if NVDA IV compresses >20% post-decision.
• Reallocate 3–5% of cyclical semicap exposure (AMAT, LRCX) into consumer staples ETF XLP if decision is a denial or delays >90 days; reverse if approval occurs and order flows are validated.
• Monitor three triggers over the next 30–90 days before scaling: (1) official Commerce ruling, (2) NVDA guidance/order-confirmation in earnings call, (3) first shipment/activation reports from Chinese hyperscalers — scale in/out rules: add 50% position on two triggers, exit 75% on denial or sanction announcement.